J&J backs down from its planned 340B rebate model

By Susan Morse in Healthcare Finance News, Reimbursement, Finance, Financial management, Life Sciences, Pharma, Population and Public Health, Regulation, Business, Care, Public Policy
October 1, 2024

The drugmaker says it believes the rebate model is legally permissible and needed to improve the integrity of the 340B program.

Read the full post on News Feed

Susan Morse